Is Adaptive Biotechnologies (ADPT) a Worthy Investment Choice?

Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Aristotle Core Equity” first quarter 2022 investor letter – a copy of which can be downloaded here. For the first quarter of 2022, Aristotle Atlantic’s Core Equity Composite posted a total return of -6.79% gross of fees (-6.89% net of fees), underperforming the S&P 500 Index, which recorded a total return of -4.60%. Try to spend some time looking at the fund’s top 5 holdings to be informed about their best picks for 2022.

In its Q1 2022 investor letter, Aristotle Capital Management Core Equity Fund mentioned Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and explained its insights for the company. Founded in 2009, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a Seattle, Washington-based commercial company with a $1.1 billion market capitalization. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) delivered a -70.71% return since the beginning of the year, while its 12-month returns are down by -78.26%. The stock closed at $8.22 per share on May 27, 2022.

Here is what Aristotle Capital Management Small Cap Equity has to say about Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in its Q1 2022 investor letter:

“Shares of Adaptive Biotechnologies were weak in the first quarter, despite the company reporting better-than-expected results and guiding in line with estimates in mid-February. High-valuation growth companies like Adaptive Biotechnologies continued to be pressured during the quarter, as investors weighed the risk of inflation and rising Treasury yields. On a positive note, clonoSEQ volumes continue to be strong and we believe 2022 is shaping up to be a catalyst rich year for the company.”

SFIO CRACHO/Shutterstock.com

Our calculations show that Adaptive Biotechnologies Corporation (NASDAQ:ADPT) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) was in 28 hedge fund portfolios at the end of the first quarter of 2022, compared to 22 funds in the previous quarter. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) delivered a -43.04% return in the past 3 months. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q1 page.

Disclosure: None. This article is originally published at Insider Monkey.